These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 24500405)

  • 1. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.
    Larsson M; Rayzman V; Nolte MW; Nickel KF; Björkqvist J; Jämsä A; Hardy MP; Fries M; Schmidbauer S; Hedenqvist P; Broomé M; Pragst I; Dickneite G; Wilson MJ; Nash AD; Panousis C; Renné T
    Sci Transl Med; 2014 Feb; 6(222):222ra17. PubMed ID: 24500405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XII: a drug target for safe interference with thrombosis and inflammation.
    Kenne E; Renné T
    Drug Discov Today; 2014 Sep; 19(9):1459-64. PubMed ID: 24993156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor XII: a novel target for safe prevention of thrombosis and inflammation.
    Kenne E; Nickel KF; Long AT; Fuchs TA; Stavrou EX; Stahl FR; Renné T
    J Intern Med; 2015 Dec; 278(6):571-85. PubMed ID: 26373901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs.
    Wilbs J; Kong XD; Middendorp SJ; Prince R; Cooke A; Demarest CT; Abdelhafez MM; Roberts K; Umei N; Gonschorek P; Lamers C; Deyle K; Rieben R; Cook KE; Angelillo-Scherrer A; Heinis C
    Nat Commun; 2020 Aug; 11(1):3890. PubMed ID: 32753636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.
    Pireaux V; Tassignon J; Demoulin S; Derochette S; Borenstein N; Ente A; Fiette L; Douxfils J; Lancellotti P; Guyaux M; Godfroid E
    J Am Coll Cardiol; 2019 Oct; 74(17):2178-2189. PubMed ID: 31648711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.
    May F; Krupka J; Fries M; Thielmann I; Pragst I; Weimer T; Panousis C; Nieswandt B; Stoll G; Dickneite G; Schulte S; Nolte MW
    Br J Haematol; 2016 Jun; 173(5):769-78. PubMed ID: 27018425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities.
    Worm M; Köhler EC; Panda R; Long A; Butler LM; Stavrou EX; Nickel KF; Fuchs TA; Renné T
    Ann Transl Med; 2015 Oct; 3(17):247. PubMed ID: 26605293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection.
    Demoulin S; Godfroid E; Hermans C
    J Thromb Haemost; 2021 Feb; 19(2):323-329. PubMed ID: 33047454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
    Xu Y; Cai TQ; Castriota G; Zhou Y; Hoos L; Jochnowitz N; Loewrigkeit C; Cook JA; Wickham A; Metzger JM; Ogletree ML; Seiffert DA; Chen Z
    Thromb Haemost; 2014 Apr; 111(4):694-704. PubMed ID: 24336918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal circulation without bleeding.
    Schmaier AH
    Sci Transl Med; 2014 Feb; 6(222):222fs7. PubMed ID: 24500403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New agents for thromboprotection. A role for factor XII and XIIa inhibition.
    Labberton L; Kenne E; Renné T
    Hamostaseologie; 2015; 35(4):338-50. PubMed ID: 25609114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XIIa as a Novel Target for Thrombosis: Target Engagement Requirement and Efficacy in a Rabbit Model of Microembolic Signals.
    Barbieri CM; Wang X; Wu W; Zhou X; Ogawa AM; O'Neill K; Chu D; Castriota G; Seiffert DA; Gutstein DE; Chen Z
    J Pharmacol Exp Ther; 2017 Mar; 360(3):466-475. PubMed ID: 28035006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.
    Nickel KF; Long AT; Fuchs TA; Butler LM; Renné T
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):13-20. PubMed ID: 27834692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging.
    Walsh APG; Yu E; McFadyen JD; Bongcaron V; Moon MJ; Huang A; Arthur JF; Muir IL; Rayzman V; Panousis C; Wang X; Peter K
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1031-1040. PubMed ID: 37078286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.
    Cheng Q; Tucker EI; Pine MS; Sisler I; Matafonov A; Sun MF; White-Adams TC; Smith SA; Hanson SR; McCarty OJ; Renné T; Gruber A; Gailani D
    Blood; 2010 Nov; 116(19):3981-9. PubMed ID: 20634381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation.
    Xu P; Zhang Y; Guo J; Li H; Konrath S; Zhou P; Cai L; Rao H; Chen H; Lin J; Cui Z; Ji B; Wang J; Li N; Liu DP; Renné T; Wang M
    Nat Commun; 2024 Sep; 15(1):7898. PubMed ID: 39266545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Krueger K; Schmutz A; Zieger B; Kalbhenn J
    Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe anticoagulation when heart and lungs are "on vacation".
    Dobrovolskaia MA; McNeil SE
    Ann Transl Med; 2015 May; 3(Suppl 1):S11. PubMed ID: 26046056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose.
    Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C
    Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.